Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Vehreschild MJGT, Atanasov P, Yurko K, Oancea C, Popov G, Smesnoi V, Placinta G, Kohlhof H, Vitt D, Peelen E, Mihajlović J, Muehler AR. Vehreschild MJGT, et al. Infect Dis Ther. 2022 Dec;11(6):2159-2176. doi: 10.1007/s40121-022-00690-0. Epub 2022 Oct 15. Infect Dis Ther. 2022. PMID: 36242741 Free PMC article.
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION.
Kloka J, Friedrichson B, Dauth S, Foldenauer AC, Bulczak-Schadendorf A, Vehreschild MJGT, Matos FM, Riera-Mestre A, van Asselt ADI, De Robertis E, Juskeviciene VT, Meybohm P, Tomescu D, Lacombe K, Stehouwer CDA, Zacharowski K; IXION Collaboration Group. Kloka J, et al. Among authors: vehreschild mjgt. Trials. 2022 Aug 19;23(1):688. doi: 10.1186/s13063-022-06609-x. Trials. 2022. PMID: 35986390 Free PMC article. Clinical Trial.
Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Böll B, Kaul I, Wassmer G, Hallek M, Scheid C, Cornely OA. Vehreschild JJ, et al. Int J Antimicrob Agents. 2012 Feb;39(2):130-4. doi: 10.1016/j.ijantimicag.2011.10.009. Epub 2011 Dec 12. Int J Antimicrob Agents. 2012. PMID: 22169408 Clinical Trial.
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators. Marty FM, et al. Among authors: vehreschild jj, vehreschild mjgt. Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9. Lancet Infect Dis. 2016. PMID: 26969258 Clinical Trial.
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Guery B, et al. Among authors: vehreschild mjgt. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19. Lancet Infect Dis. 2018. PMID: 29273269 Clinical Trial.
Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients.
de Castilhos J, Zamir E, Hippchen T, Rohrbach R, Schmidt S, Hengler S, Schumacher H, Neubauer M, Kunz S, Müller-Esch T, Hiergeist A, Gessner A, Khalid D, Gaiser R, Cullin N, Papagiannarou SM, Beuthien-Baumann B, Krämer A, Bartenschlager R, Jäger D, Müller M, Herth F, Duerschmied D, Schneider J, Schmid RM, Eberhardt JF, Khodamoradi Y, Vehreschild MJGT, Teufel A, Ebert MP, Hau P, Salzberger B, Schnitzler P, Poeck H, Elinav E, Merle U, Stein-Thoeringer CK. de Castilhos J, et al. Among authors: vehreschild mjgt. Clin Infect Dis. 2022 Aug 24;75(1):e1063-e1071. doi: 10.1093/cid/ciab902. Clin Infect Dis. 2022. PMID: 34694375 Free PMC article.
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.
Vehreschild MJGT, Ducher A, Louie T, Cornely OA, Feger C, Dane A, Varastet M, Vitry F, de Gunzburg J, Andremont A, Mentré F, Wilcox MH. Vehreschild MJGT, et al. J Antimicrob Chemother. 2022 Mar 31;77(4):1155-1165. doi: 10.1093/jac/dkab474. J Antimicrob Chemother. 2022. PMID: 35016205 Free PMC article. Clinical Trial.
Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients.
Hastert FD, Henss L, von Rhein C, Gerbeth J, Wieters I, Borgans F, Khodamoradi Y, Zacharowski K, Rohde G, Vehreschild MJGT, Schnierle BS. Hastert FD, et al. Among authors: vehreschild mjgt. Viruses. 2022 Apr 23;14(5):882. doi: 10.3390/v14050882. Viruses. 2022. PMID: 35632624 Free PMC article.
227 results